DNA repair

Mblue Labs Discovers Anti-Aging Power In Methylene Blue, Launches Bluelene Face&Neck Remodel Mask

Retrieved on: 
Wednesday, March 13, 2024
Scientific Reports, Health, Skin care, ECM, Face, Retinol, Radical (chemistry), Cell nucleus, Peptide, Extracellular matrix, DNA, Research, ROS, Mitochondrion, Methylene blue, Skin, Collagen, DNA repair, UMD, Identity matrix, Human, Ageing, Neck, Cosmetics

Bethesda, Maryland--(Newsfile Corp. - March 13, 2024) - Mblue Labs proudly announces the debut of the Face & Neck Remodel Mask, a groundbreaking addition to their renowned skincare brand, Bluelene.

Key Points: 
  • Bethesda, Maryland--(Newsfile Corp. - March 13, 2024) - Mblue Labs proudly announces the debut of the Face & Neck Remodel Mask, a groundbreaking addition to their renowned skincare brand, Bluelene.
  • Mblue Labs, a woman and minority-owned business, is dedicated to advancing skincare science, and this latest product embodies their commitment to unparalleled innovation.
  • Methylene Blue penetrates skin cells at the mitochondrial level, creating cell health and proliferation.
  • To view an enhanced version of this graphic, please visit:
    The Face & Neck Remodel Mask features a powerful blend of the latest age-reversal ingredients, including Methylene Blue, Growth Factors, Advanced Peptides, and Niacinamide.

Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS(G12C) Inhibitors at AACR Annual Meeting 2024

Retrieved on: 
Tuesday, April 2, 2024
WEE1, Medication, Research, 2D, Cell death, DNA repair, Colorectal cancer, Patient, SAN, DNA, Cell cycle, 3D, Lung cancer, AACR, Cancer, Poster, Therapy, Pharmaceutical industry

Research demonstrated that the Company’s WEE1 inhibitor, azenosertib, exerts synergistic anti-tumor activity when combined with KRASG12C inhibitors.

Key Points: 
  • Research demonstrated that the Company’s WEE1 inhibitor, azenosertib, exerts synergistic anti-tumor activity when combined with KRASG12C inhibitors.
  • Our preclinical data demonstrate that combining azenosertib with KRASG12C inhibitors dramatically enhances anti-tumor activity.
  • The research that will be presented at AACR Annual Meeting 2024 evaluated the anti-tumor activity of azenosertib when administered in combination with KRASG12C inhibitors sotorasib or adagrasib.
  • The data demonstrated synergistic cell growth inhibition across a panel of KRASG12C cell lines in both 2D and 3D assays.

Accent Therapeutics Presents Data Supporting Two Lead Programs at AACR 2024 Annual Meeting

Retrieved on: 
Monday, April 8, 2024
BRCA, DNA repair, Mitosis, Apoptosis, Breast, PD, RME, Patient, DHX9, Neoplasm, Data, RNA, DNA, Cancer, Accent, Enzyme, AACR, Therapy, Breast cancer, BRCA2, Pharmaceutical industry

LEXINGTON, Mass., April 8, 2024 /PRNewswire/ -- Accent Therapeutics, a biopharmaceutical company pioneering a novel class of small molecule precision cancer therapeutics presents advances in cancer targeting, including data on DHX9 and KIF18A inhibitor activity in multiple tumor types, at the 2024 American Association for Cancer Research (AACR) Annual Meeting, taking place April 5-10 in San Diego, California.

Key Points: 
  • "Accent has expanded the potential of our two lead programs in preclinical investigations, and we are excited for the promise they hold for addressing cancers with high unmet clinical need," said Robert A. Copeland, Ph.D., President, Founder, and Chief Scientific Officer of Accent Therapeutics.
  • "Our results reveal that DHX9 and KIF18A inhibition are potent therapeutic strategies that stand to benefit large patient populations.
  • These findings validate our systematic approach to tapping the rich therapeutic potential of our target space."
  • These data are highlighted in a presentation entitled "DHX9 inhibition as a novel therapeutic for cancer with loss-of-function mutations in DNA damage repair genes BRCA1 and BRCA2."

Orphan designation: Veliparib Treatment of ovarian cancer, 17/12/2010 Withdrawn

Retrieved on: 
Tuesday, April 9, 2024
Eurostat, Diagnosis, Civil service commission, Ovarian cancer, Enzyme, DNA repair, Abbott Laboratories, Survival, Disease, Patient, Committee, Knowledge, DNA, Cancer, Female, Regulation, Laboratory, EMA, IRIS, Ludwigshafen, Woman, PARP, European, COMP, Sponsor, European Commission, Fibroadenoma, Safety, Marketing, Medicine, Pharmaceutical industry

Orphan designation: Veliparib Treatment of ovarian cancer, 17/12/2010 Withdrawn

Key Points: 


Orphan designation: Veliparib Treatment of ovarian cancer, 17/12/2010 Withdrawn

Eisbach and Cancer Focus Fund Announce $4.5 Million Investment to Support First-in-Human Phase 1/2 Trial of EIS-12656 for Refractory Advanced Solid Tumors

Retrieved on: 
Thursday, March 21, 2024
Cancer, Principal, Enzyme, DNA repair, Biochemistry, Survival, Professor, Monroe Dunaway Anderson, Patient, Neoplasm, DNA, History, Breast, Prostate, Protein, University, MD Anderson Cancer Center, PARP, Therapy, ALC1, Chromatin, CSO, LP, Pharmaceutical industry

EIS-12656 is a small molecule designed to treat tumors that are refractory or resistant to PARP inhibitors.

Key Points: 
  • EIS-12656 is a small molecule designed to treat tumors that are refractory or resistant to PARP inhibitors.
  • By hindering DNA repair, PARP inhibitors cause tumor cell death, and they have been effective therapies for many ovarian, breast, prostate, and pancreatic cancers.
  • EIS-12656 inhibits the chromatin remodeling enzyme ALC1, which is critical to the DNA repair process associated with PARP activation.
  • EIS-12656 was developed by Eisbach to disrupt DNA-damage-dependent PARP activation at an early stage of the repair process.

Bionano Announces Publication of a Breast Cancer Study Showing that the Number of SVs Detected with OGM May Be Related to Prognosis, Tumor Progression and Chemotherapy Resistance

Retrieved on: 
Tuesday, March 19, 2024
Ovarian cancer, DNA repair, Breast, SAN, Neoplasm, DNA, HBOC, Doctor of Philosophy, Medicine, Genomics, Chromothripsis, SVS, Breast cancer, HRD, BRCA2, OGM, BRCA1, Drug resistance, Medical imaging

HBOC syndrome is estimated to cause 5-10% of all breast cancers and is commonly characterized by harmful germline mutations in the BRCA1 or BRCA2 genes.

Key Points: 
  • HBOC syndrome is estimated to cause 5-10% of all breast cancers and is commonly characterized by harmful germline mutations in the BRCA1 or BRCA2 genes.
  • The study authors selected OGM for this analysis due to its ability to detect multiple classes of SVs with genome-wide coverage, high resolution and accuracy.
  • Eight novel gene fusions were identified by OGM, including three that had not previously been detected by other methods of analysis.
  • “We are pleased to see the publication of this study, which highlights OGM as a promising tool for detecting novel variants in HBOC-related breast cancer that have oncogenic potential.

Rocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia

Retrieved on: 
Tuesday, April 2, 2024
Biotechnology, Pharmaceutical, Oncology, General Health, Health, Genetics, Clinical Trials, Other Health, Transplant, DNA repair, Medication, Biologics license application, MAA, Risk, FANCA, Patient, Fanconi anemia, Pharming, DNA, BMF, HSCT, EMA, Bone marrow failure, Death, Birth, Life, MBA, European Medicines Agency, Marketing, FA, Disorder, FDA, BLA, Genetic disorder, Food

“The acceptance of the MAA for RP-L102 marks an important step forward in our goal of bringing this potential gene therapy treatment to patients impacted by this devastating childhood disorder.

Key Points: 
  • “The acceptance of the MAA for RP-L102 marks an important step forward in our goal of bringing this potential gene therapy treatment to patients impacted by this devastating childhood disorder.
  • Currently, there are no existing options to potentially prevent BMF for patients with FA,” said Kinnari Patel, Pharm.D., MBA, President, Head of R&D and Chief Operating Officer, Rocket Pharma.
  • The safety profile was highly favorable with no significant safety signals, and the treatment, administered without any cytotoxic conditioning, was well tolerated.
  • The Biologics License Application (BLA) for FA remains on track for submission to the U.S. Food and Drug Administration (FDA) in the first half of 2024.

National Cancer Center Names Michelle Stack CEO Following Retirement of Long-Time Leader Regina English

Retrieved on: 
Wednesday, March 13, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Diagnosis, DNA repair, Brain, Beauty, Education, Research, DNA, Cancer, Prostate cancer, National Cancer Center, Breast cancer, Melanoma, Therapy, NCC, Management

The Board of National Cancer Center is pleased to announce that Michelle Stack has joined as CEO.

Key Points: 
  • The Board of National Cancer Center is pleased to announce that Michelle Stack has joined as CEO.
  • Ms. Stack replaces long-time leader Regina English , who is now Executive Director Emerita and Board member-at-large.
  • “We are delighted to name Michelle as CEO of National Cancer Center,” said Barry Peek , President of the Board.
  • NCC runs six cancer research programs: Aggressive Cancer Project; Fighting Childhood Leukemia; The Breast Cancer Project; Children’s Cancer Project; Prostate Cancer Project and the NCC Project, which funds research showing particular promise in the following areas: brain tumors, melanoma, DNA repair, anti-cancer therapies, gene mutations and targeted therapeutics for breast cancer.

Eternity Biotech Launches Crowdfunding Campaign on Wefunder to Accelerate Anti-Aging Product Development

Retrieved on: 
Tuesday, April 2, 2024
DNA repair, Gene, The Company, DNA, Research, Growth, Cell division, Apoptosis, Regulation CF

NEW YORK, April 2, 2024 /PRNewswire/ -- Eternity Biotech, Inc. (the "Company", "Eternity"), a biotechnology company dedicated to finding solutions for longer, healthier lives, today announced the launch of a crowdfunding campaign on Wefunder to advance its anti-aging product development.

Key Points: 
  • NEW YORK, April 2, 2024 /PRNewswire/ -- Eternity Biotech, Inc. (the "Company", "Eternity"), a biotechnology company dedicated to finding solutions for longer, healthier lives, today announced the launch of a crowdfunding campaign on Wefunder to advance its anti-aging product development.
  • After replicating these results in human cells, Eternity looks to develop this technology and identify a novel candidate in the anti-aging space.
  • "With this campaign, we look to usher in a new era of growth and development for Eternity and within the broader anti-aging sector of life science research," said Joseph Hernandez, Chairman and Chief Executive Officer of Eternity.
  • To learn more about Eternity's technology and participate in this campaign, visit Eternity's page on Wefunder .

Making Long-Term Memories Requires Nerve-Cell Damage

Retrieved on: 
Wednesday, March 27, 2024
Inflammation, Radulović, Psychiatry, Brain, TLR9, COVID, Gene, DNA repair, DSM-IV codes, Cell division, Genome instability, University Medical Center, Infection, Memory, Organelle, Hippocampus, Mouse, DNA, Albert Einstein, Nature, Cancer, Toll-like receptor 9, Neuron, Northwestern University, Doctor of Philosophy, Alzheimer's disease, Genome, Aarhus University, Cytoplasm, Cell, Dominic, B.A, Encephalitis, Ageing, Vaccine

"But our findings suggest that inflammation in certain neurons in the brain's hippocampal region is essential for making long-lasting memories."

Key Points: 
  • "But our findings suggest that inflammation in certain neurons in the brain's hippocampal region is essential for making long-lasting memories."
  • But looking more closely, we found, to our surprise, that TLR9 was activated only in clusters of hippocampal cells that showed DNA damage."
  • But in this population of hippocampal neurons, the DNA damage appeared to be more substantial and sustained.
  • Importantly, the researchers found that blocking the TLR9 inflammatory pathway in hippocampal neurons not only prevented mice from forming long-term memories but also caused profound genomic instability, i.e, a high frequency of DNA damage in these neurons.